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Metabolomics is used in systems biology to enhance the understanding of complex
disease processes, such as cancer. Head and neck cancer (HNC) is an epithelial
malignancy that arises in the upper aerodigestive tract and affects more than half a
million people worldwide each year. Recently, significant effort has focused on integrating
multiple “omics” technologies for oncological research. In particular, research has
been focused on identifying tumor-specific metabolite profiles using different sample
types (biological fluids, cells and tissues) and a variety of metabolomic platforms and
technologies. With our current understanding of molecular abnormalities of HNC, the
addition of metabolomic studies will enhance our knowledge of the pathogenesis of
this disease and potentially aid in the development of novel strategies to prevent and
treat HNC. In this review, we summarize the proposed hypotheses and conclusions from
publications that reported findings on the metabolomics of HNC. In addition, we address
the potential influence of host-microbe metabolomics in cancer. From a systems biology
perspective, the integrative use of genomics, transcriptomics and proteomics will be
extremely important for future translational metabolomic-based research discoveries.
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INTRODUCTION
The incidence of head and neck cancer (HNC) exceeds half a million cases annually worldwide
and accounts for approximately 3% of adult malignancies (Johnson et al., 2011; National Cancer
Institute, 2013). HNC is defined as epithelial malignancies that arise in the aerodigestive tract
(paranasal sinuses, nasal and oral cavity, pharynx and larynx) and can metastasize to different
locations (Rezende et al., 2010). About 75% of HNCs are oral cancers and 90% of oral cancers
are diagnosed as oral squamous cell carcinomas (OSCC) (Rezende et al., 2010; National Cancer
Institute, 2013). Despite therapeutic and technological advances, the prognosis for HNC has not
improved in decades due to its malignant and recurrent properties (Forastiere et al., 2001; Mao
et al., 2004). The most widely accepted risk factors for HNC include tobacco (smoked or chewed),
alcohol use, and human papillomavirus (HPV) infection (Gillison, 2004; Schmidt et al., 2004).
However, these risk factors alone cannot explain the observed incidence and pathogenesis of HNC,
since some patients are not in these risk categories. Thus, it is likely that other unknown factors
play important roles in tumorigenesis, tumor progression and metastasis of HNC.
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There has been an increasing trend to incorporate “omics”
technology, including metabolomics, into oncological research
(Vucic et al., 2012; Cho, 2013; Armitage and Barbas, 2014;
Yu and Snyder, 2016). Investigators have explored different
technologies and analytical methods to better understand the
metabolomic properties of cancers, includingHNC (Bathen et al.,
2010; Blekherman et al., 2011; Beger, 2013; Liesenfeld et al.,
2013; Olivares et al., 2015). As more independent reports on
metabolomics of HNC are being published, a comprehensive
meta-analysis of these large “omics” data sets will be of
potential value in the near future to enhance translational
studies. Specifically, metabolomic studies can help to potentially
identify clinically relevant biomarkers that may be useful in early
detection of cancer, to enhance the accuracy of diagnosis and
prognosis, and to aid in the development of new drug targets to
help improve therapeutic outcomes (Olivares et al., 2015; Yu and
Snyder, 2016).
The objective of this mini-review is to summarize and discuss
the published studies on HNC metabolomics. We will discuss
the different technological tools utilized in metabolomics, and
focus on the findings from studies that used different types
of patient samples (i.e., saliva, serum, blood, urine, tissues).
In addition to the host-metabolomic profiles, we discuss the
potential relationship and influence of the microbial metabolome
in cancers. By coupling metabolomics data with other omics
data, we can achieve a greater understanding of complex cancer
processes and derive new information that may help to better
target aggressive and malignant cancer types, such as HNC.
Biological Samples Used for Head and
Neck Cancer Metabolomics
A broad array of biological fluids, such as saliva, blood and urine
have been used in metabolomic-based studies (Nagana Gowda
et al., 2008; Psychogios et al., 2011; Bouatra et al., 2013; Dame
et al., 2015). These biofluids contain hundreds to thousands of
detectable metabolites that can be obtained non- or minimally
invasively (Beger, 2013). In addition, cell and tissue extracts can
be a source of samples for metabolomic-based studies (Beger,
2013). With current diagnostic procedures requiring a tissue
biopsy, a portion of the tissue samples can be harvested for
further metabolomic analyses. The following discussion will
focus on the findings, postulated hypotheses, and conclusions
from the published metabolomic studies that used different
biofluids and cell/tissue extracts to study HNC metabolomics.
Saliva Metabolomics
Saliva is an important biological fluid required for multiple
functions, including speech, taste, digestion of foods, antiviral
and antibacterial protection, to maintain adequate oral health
(Loo et al., 2010; Spielmann and Wong, 2011). Saliva is readily
available, and the collection process is simple and non-invasive.
Abbreviations: Ala, (alanine); Asp, (aspartate); Bet, (betaine); Cit, (citrate);
Cr, (creatinine); Cho, (choline); Glu, (glutamate); Gluc, (glucose); Gln,
(glutamine); Glut, (glutathione); Gly, (glycine); GPC, (glycerophosphocholine);
His, (histidine); Ile, (isoleucine); Lac, (lactate); Leu, (leucine); Lys, (lysine); PCho,
(phosphocholine); Phe, (phenylalanine); Pro, (proline); Pyr, (pyruvate); Tau,
(taurine); Thr, (threonine); Tyr, (tyrosine); Val, (valine).
Thus, saliva has been a popular medium for “omics” based
research studies (Zhang et al., 2012; Cuevas-Córdoba and
Santiago-García, 2014). Two types of saliva that can be used
for metabolomics studies are stimulated and unstimulated whole
saliva. These two saliva types vary in their chemical composition,
so it is important to identify the specific type of saliva that was
used for the study (Humphrey and Williamson, 2001; Carpenter,
2013; Cuevas-Córdoba and Santiago-García, 2014).
Amongst different HNC types, OSCC is associated with a
high morbidity rate and a poor 5-year survival rate of less than
50% (Epstein et al., 2002; Mao et al., 2004). To improve the
prognosis for HNC, investigators have proposed using saliva
metabolites to differentiate between precancerous and malignant
lesions. Using hierarchical principal component analysis (PCA)
and discriminate analysis algorithms, Yan and colleagues were
able to distinguish between OSCC and its precancerous lesions
oral lichen planus (OLP) and oral leukoplakia (OLK) (Yan et al.,
2008; Table 1). Although the OLP and OLK groups were not
as well separated in the PCA plot, the OSCC group showed a
clear separation from the healthy and precancerous groups (Yan
et al., 2008). In addition, Wei and others used ultra-performance
liquid chromatography coupled with quadrupole/time-of-flight
spectrometry (UPLC-QTOFMS) analysis to identify a signature
panel of salivary metabolites that could distinguish OSCC from
healthy controls (Wei et al., 2011; Table 1). Wei selected a
panel of five salivary metabolites, which included γ-aminobutyric
acid, phenylalanine, valine, n-eicosanoic acid and lactic acid.
This combination of metabolites accurately predicted and
distinguished OSCC from the control samples, suggesting
that metabolomic approaches could complement the clinical
detection of OSCC for improved diagnosis and prognosis (Wei
et al., 2011).
Work presented by Almadori and colleagues discovered
that salivary glutathione (antioxidant), but not uric acid
(antioxidant), was significantly increased in patients with oral
and pharyngeal SCC compared to healthy controls (Almadori
et al., 2007; Table 1). However, although there were significant
alterations in the glutathione levels potentially due to metabolism
of malignant cells, the concentrations were too inconsistent
to suggest glutathione as a definitive SCC diagnostic marker
(Almadori et al., 2007). Furthermore, Sugimoto and colleagues
identified 28 metabolites that correctly differentiated oral
cancers from control samples in their study (Sugimoto et al.,
2010). Among these differentially expressed metabolites, salivary
polyamine levels were markedly higher in oral cancer samples
compared to other cancer samples (breast and pancreatic)
and controls (Sugimoto et al., 2010). Polyamines are small
molecules derived from amino acids that are essential for
many biological functions (Dimery et al., 1987; Pegg, 2009).
Increased polyamine levels have been associated with increased
cell proliferation, decreased apoptosis and elevated expression
of genes affecting tumor invasion and metastasis (Gerner and
Meyskens, 2004). Thus, it is hypothesized that polyamine
homeostasis is important for regulation of cancer related
functions, such as cell proliferation and apoptosis.
Based on published studies that analyzed the salivary
metabolome of HNC, there is a general consensus that unique
Frontiers in Physiology | www.frontiersin.org 2 November 2016 | Volume 7 | Article 526
Shin et al. Metabolomics of Head and Neck Cancer
TABLE 1 | Summary of metabolomic-based studies on head and neck cancers.
Subjects Cancer Sample Detection
method
Metabolomic findings References
50 HNSCC
77 healthy
HNSCC Saliva HPLC Increased: Glutathione Almadori et al., 2007
20 OSCC,
20 OLP
7 OLK
11 healthy
OSCC
OLP
OLK
Saliva HPLC/MS Metabolic profiling data distinguished between OSCC,
OLP and OLK
Yan et al., 2008
69 oral cancer patients
87 healthy
Oral
cancer
Saliva CE-TOF-MS 28 differentially expressed metabolites were detected
and was used to predict oral cancer outcome
Sugimoto et al., 2010
37 OSCC
32 oral leukoplakia
34 healthy
OSCC
Oral
leukoplakia
Saliva UPLC-
QTOFMS
41 metabolites distinguished OSCC from control, 61
distinguished OSCC from OLK, and 27 distinguished
OLK from control
Wei et al., 2011
33 OSCC
5 OLK
28 healthy
OSCC
OLK
Healthy
Blood
(plasma)
1H NMR At least 17 metabolites were differentially expressed
and differentiated OSCC from healthy
Zhou et al., 2009
15 OSCC
10 healthy
OSCC Blood
(serum)
1D 1H and 2D
1H J-resolved
NMR
Altered energy metabolism:
Lipolysis (increased levels of ketone bodies)
TCA cycle (i.e., ↓citrate, succinate, formate)
Amino acid catabolism (i.e., ↑ 2-hydroxbutyrate,
ornithine, asparagine)
Tiziani et al., 2009
25 HNSCC
(Of these patients, 17 used for
serum and 19 used for tissue
analysis)
HNSCC Blood
(serum)
Tissues
GC/MS Serum:
↑ Glycolysis, ↓ Amino acids Tissues
↑ Amino acids, ↓ Glycolysis
Yonezawa et al., 2013
37 OSCC
32 OLK
34 healthy
OSCC
OLK
Urine GC-MS Increased:
Alanine, tyrosine, valine, serine, and cysteine
Decreased: Hippurate and 6-hydroxynicotic acid
Regression model based on valine and
6-hydroxynicotic acid
yielded an accuracy of 98.9%, sensitivity of 94.4%,
specificity of 91.4%, and positive predictive value of
91.9% in distinguishing OSCC from the controls
Xie et al., 2012
In vitro:
19 HNSCC
13 healthy
3 metastatic cervical lymph node
SCC cell line
In vivo:
7 HNSCC
7 healthy
HNSCC Tissues 1H MRS Mean choline/creatine ratio was higher in HNSCC
samples. Several amino acids including alanine,
isoleucine, glutathione, histidine, valine, lysine and
polyamine were differentially found in HNSCC samples
Mukherji et al., 1997
85 HNSCC
50 healthy
HNSCC Tissues 1H MRS Increased:
Taurine, choline, glutamic acid, lactic acid, lipid
El-Sayed et al., 2002
159 OSCC
(Tumor and neighboring margins
and bed tissues)
OSCC Tissues HR-MAS NMR Increased:
Acetate, glutamate, lactate, choline, phosphocholine,
glycine, taurine, leucine, isoleucine, valine, lysine, and
alanine Decreased:
Creatine, polyunsaturated fatty acids
Srivastava et al., 2011
22 HNSCC (matched samples
divided into 18NAT, 18 tumor
and 7 LN-Met)
HNSCC Tissues HR-MAS 1H
NMR
HNSCC and LN-Met tissues showed elevated levels
of lactate, amino acids and decreased levels of
triglycerides
Somashekar et al., 2011
(Continued)
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TABLE 1 | Continued
Subjects Cancer Sample Detection
method
Metabolomic findings References
5 HNSCC cell lines
3 primary normal human oral
keratinocytes from patients
HNSCC Cells 1H NMR 21 differentially expressed metabolites:
Increased:
Lactate, isoleucine, valine, alanine, glutamine,
glutamate,
aspartate, glycine, phenylalanine, tyrosine,
choline-containing compounds, creatine, taurine,
glutathione
Decreased: Triglycerides
Tripathi et al., 2012
2 cell lines (HNSCC cells and
stem-like cancer cells)
HNSCC Cells Cap IC-MS Changes in energy metabolism pathways: Glycolysis
and TCA cycle
Wang et al., 2014
Cap IC-MS, Capillary anion exchange ion chromatography-mass spectrometry; CE-TOF/MS, Capillary electrophoresis-time-of-flight mass spectrometry; GC/MS, Gas
chromatography/mass spectrometry; 1H-NMR, Proton nuclear magnetic resonance; HR-MAS; High resolution magic angle spinning; 1H-MRS, Proton magnetic resonance
spectroscopy; HPLC, High performance liquid chromatography; LC/GC, Liquid chromatography/gas chromatography; NMR, Nuclear magnetic resonance; UPLC-QTOFMS,
Ultra-performance liquid chromatography coupled with quadrupole/time-of-flight spectrometry; LN-Met, lymph node metastasis.
metabolites specific to HNC exist. However, due to differences
in detection and analytical methods, the current data still lacks
coherency, and a common HNC metabolomic signature has yet
to be identified.
Blood and Urine Metabolomics
In addition to saliva, blood and urine are commonly used for
metabolomic-based studies (Psychogios et al., 2011; Bouatra
et al., 2013). Blood is divided into plasma—a cellular portion
containing red and white blood cells and platelets, and serum—
a non-cellular protein-rich liquid separately obtained following
blood coagulation. Both plasma and serum contain a wide variety
of metabolites, and current studies suggest that plasma and
serum are similar in terms of metabolite content within the
aqueous phase (Psychogios et al., 2011). Importantly, numerous
studies have demonstrated that an altered chemical and protein
metabolic composition can now be detected in blood samples
obtained from subjects with pathology or diseases, such as
cancer (Psychogios et al., 2011; DeBerardinis and Thompson,
2012). Tiziani and colleagues reported that OSCC patients
exhibited abnormal metabolic activity in blood serum, wherein
altered activity related to lipolysis, the TCA cycle and amino
acid catabolism was detected (Tiziani et al., 2009; Table 1).
For example, there was an increased level of ketone bodies
present in OSCC samples, suggesting that increased lipolysis
was a backup mechanism for energy production (Tiziani et al.,
2009). Furthermore, a common signature for many cancers
includes a high rate of glycolysis followed by lactic acid
fermentation in the cytosol, rather than by a comparatively
low rate of glycolysis followed by oxidation of pyruvate in
the mitochondria, known as the “Warburg effect.” Similarly in
HNC, Tiziani demonstrated that OSCC tumors relied heavily on
glycolysis as a main energy source (Warburg, 1956; Tiziani et al.,
2009).
Yonezawa and others identified several metabolites that were
altered in serum and tissue samples of HNSCC patients who
experienced relapse (Yonezawa et al., 2013). The four metabolites
that were significantly altered were glucose, methionine, ribulose,
and ketoisoleucine (Yonezawa et al., 2013). Interestingly, when
the authors compared the metabolomic profiles of the OSCC
serum and tissue samples, an inverse relationship was observed
in the differentially expressed metabolites (Yonezawa et al.,
2013; Table 1). Metabolites associated with glycolytic pathways
(i.e., glucose) were lower in the tissues, whereas amino acids
(i.e., valine, tyrosine, serine, and methionine) were expressed
in higher levels in the tissues than the serum (Yonezawa
et al., 2013). In addition, the serum metabolomic profiles
differed between patients with or without HNSCC relapse
(Yonezawa et al., 2013). Several other studies further support
that serum and plasma samples from HNC subjects possess
distinct metabolomic profiles. For example, elevated levels
of choline-containing compounds were detected in OSCC
samples in numerous studies (Maheshwari et al., 2000; El-
Sayed et al., 2002; Bezabeh et al., 2005; Tiziani et al., 2009;
Zhou et al., 2009). Choline is an important constituent
of phospholipid metabolism in cellular membranes and is
considered a biomarker for cancer cell proliferation, survival and
malignancy (Ackerstaff et al., 2003; Glunde et al., 2006, 2011).
Through our comprehensive analysis, choline was identified as
one of the metabolites that was consistently over expressed in
HNC samples regardless of sample types (Figure 1B). Studies
have suggested a link between cancer feedback cell signaling and
choline metabolism (Aboagye and Bhujwalla, 1999; Ackerstaff
et al., 2003; Janardhan et al., 2006; Glunde et al., 2011;
Ridgway, 2013). Thus, an abnormal cholinemetabolism in cancer
has gained much attention and is regarded as a metabolic
hallmark for tumor development and progression (Glunde et al.,
2011).
The use of urine samples in HNC metabolomic studies is not
as common compared to the other types of biofluids mentioned
above. However, urine is widely used by metabolomic researchers
for other conditions or diseases due to its ease of collection
and the wide coverage of metabolites that is possible with urine
samples (Bouatra et al., 2013). Thus far, there has only been a
single study reported on HNC metabolomics using urine. From
patient urine samples, Xie and colleagues identified a panel
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FIGURE 1 | Head and neck cancer metabolism. (A) Proposed schematic representation of HNC tumor microenvironment. Altered metabolism in HNC can result
in differential expression of metabolites associated with carbohydrates, lipids, amino acids, and nucleotide metabolism. The co-inhabiting microbiota of the TME can
further result in altered metabolic activity. In addition to the genomic transformation of cancer cells, diet and lifestyle (alcohol, tobacco) are risk factors contributing to
the altered cancer metabolism. (B,C) Venn diagrams showing, (B) Overlap of differentially expressed metabolites identified in HNC in saliva, blood and urine, and cells
and tissues. (C) Overlap of differentially expressed metabolites in HNC identified by different detection methods such as HPLC/GC/MS, NMR/MAS, MRS and other.
Metabolites were selected and compiled from studies in Table 1. Red, detected in increased levels; Blue, detected in decreased levels; Green, detected in increased
and decreased levels.
of differentially expressed metabolites and demonstrated their
utility by logistic regression (LR) modeling (Xie et al., 2012;
Table 1). When two metabolites, valine and 6-hydroxynicotic
acid, were inputted together in the LR prediction model,the
authors were able to identify OSCC with a 98.9% accuracy, and
a greater than 90% sensitivity, specificity and positive predictive
value (Xie et al., 2012). However, similar to saliva and blood
metabolomics, the use of urine samples for HNC metabolomics
will require further validation through more independent
studies.
Cell and Tissue Metabolomics
The current gold standard for diagnosis of HNC is a scalpel-
obtained biopsy and subsequent histopathological interpretation.
However, the current procedure is subjective and does not
capture the full heterogeneic properties of neoplastic processes,
as it is difficult to distinguish between precancerous from
cancerous and malignant lesions (Rezende et al., 2010; Yu
and Snyder, 2016). Early studies with magnetic resonance
spectroscopy (MRS) using patient tissue samples demonstrated
that a higher choline to creatine ratio was observed in HNC
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samples compared to healthy controls (Mukherji et al., 1997; El-
Sayed et al., 2002; Table 1). In addition, Mukherji and colleagues
reported that elevated levels of amino acids, such as alanine,
glutathione, histidine, isoleucine, valine, lysine, and polyamines
were more likely found in tumors compared to controls, and
similar metabolites, such as glutathione and polyamines were
also elevated in saliva associated with HNC (Mukherji et al.,
1997; Almadori et al., 2007; Sugimoto et al., 2010). Srivastava
and others used proton high-resolution magic angle spinning
magnetic resonance (HR-MAS MR) spectroscopy to identify
the metabolic perturbations of OSCC tumors compared to
healthy controls. The data revealed higher levels of lactate,
phosphocholine, choline and amino acids, and decreased levels
of PUFA and creatine in OSCC samples compared to non-
malignant samples (Srivastava et al., 2011). As previously
mentioned, higher levels of detected choline in HNC tissues
may indicate increased cancer cell proliferation and membrane
biosynthesis, as a result of reciprocal interactions between
oncogenic signaling and choline metabolism (Glunde et al.,
2011). The reduced level of creatine could also be an indication
of increased energy metabolism in tumors (Mukherji et al., 1997;
El-Sayed et al., 2002).
Somashekar and colleagues reported that tumorous tissues
biopsied from different anatomical locations (tongue, lip, oral
cavity, and larynx) displayed similar metabolomic profiles
between one another, suggesting that HNSCC tissues share
similar metabolic activity during malignant transformation
(Somashekar et al., 2011; Table 1). Primary and metastatic
HNSCC tissues both showed increased/altered levels of branched
chain amino acids, lactate, alanine, glutamine, glutamate,
glutathione, aspartate, creatine, taurine, phenylalanine,
tyrosine and choline compounds, with decreased levels of
triglycerides (Somashekar et al., 2011; Table 1). In addition,
Tripathi and others demonstrated that the cell extracts of
HNSCC displayed comparable metabolic phenotypes as
observed in the HNSCC tissues (Tripathi et al., 2012; Table 1).
Thus, based on published reports, the metabolites associated
with malignant transformation of HNC are associated with
multiple dysregulated metabolic pathways, including glycolysis,
glutaminolysis, oxidative phosphorylation, energy metabolism,
TCA cycle, osmo-regulatory and anti-oxidant mechanisms
(Figure 1; Somashekar et al., 2011; Tripathi et al., 2012; Wang
et al., 2014).
Influence of Microbial Metabolomics
The human body is a host to taxonomically diverse multi-
species microbial communities. In particular, the oral cavity
and the gut are home to hundreds of transient and resident
microbial species (Eckburg et al., 2005; Dewhirst et al., 2010).
Several publications suggest that the microbiota that colonize
the human body (particularly the oral cavity and gut) contribute
to the etiology of different types of cancers because of
their ability to alter the community composition and induce
inflammatory reactions, DNA damage and apoptosis, and an
altered metabolism (Meurman, 2010; Chen et al., 2012; Farrell
et al., 2012; Louis et al., 2014). Thus, when considering cancer-
associated metabolomics, the influence of the microbiota and its
repertoire of metabolites should also be considered, since the
microbiota are profoundly abundant in the human body and
cancerous tissues.
Colorectal cancer (CRC), like HNC, is associated with risk
factors that include diet and lifestyle (Gingras and Béliveau,
2011). Specific bacterial genera, like Fusobacterium, are found in
greater abundance in patients diagnosed with CRC, colorectal
adenomas, pancreatic cancer and HNC (Castellarin et al.,
2012; Farrell et al., 2012; Kostic et al., 2012; McCoy et al.,
2013). Accumulated data suggest that diverse polymicrobial
communities can produce a wide range of metabolites
by metabolic fermentation (Tang, 2011). For instance, gut
microorganisms can secrete a variety of metabolites that may
play a role in the etiology and prevention of complex diseases
(Heinken and Thiele, 2015). These microbial metabolites can
directly regulate and modulate the host-tumor cell metabolism
(Figure 1A); bacteria isolated from the gut can produce
metabolites that are protective or detrimental to the host tissues
and cells. For example, short-chain fatty acids (SCFAs) like
butyrate, acetate, and propionate function in the suppression
of inflammation and cancer, whereas other metabolites, such as
polyamines, are toxic and cancer-promoting at high levels (Louis
et al., 2014). Alterations in microbial diversity and function
due to known risk factors for HNC (alcohol and tobacco
use) and unknown factors could actively contribute to HNC
tumorigenesis (Schwabe and Jobin, 2013; Figure 1A).
CONCLUDING REMARKS
The complement of “omics” based approaches could significantly
enhance our understanding of the complex processes of HNC
tumorigenesis. Although, it is extremely complex, progress has
been made in integrating two or more omics data sets to
study cancer (Cho, 2013). For example, studies have examined
the molecular differences between HPV+ and HPV− HNCs
by comparing the differences in their genomic, transcriptomic,
and proteomic profiles (Sepiashvili et al., 2015). Since Otto
Warburg’s first hypothesis of the altered metabolism of cancer
cells, the field of cancer metabolomics has rapidly expanded
and revealed intriguing new data regarding metabolic pathways
associated with cancers (Warburg, 1956). With fast-moving
advancements in technology and bioinformatics, the quality of
data output and the ability to detect small molecular metabolites
has significantly improved. Thus, investigators will likely soon
be able to transition from untargeted global metabolomic
approaches to more focused targeted and mechanistic-based
metabolomic studies. In addition, with the availability of growing
public databanks, investigators can now search for specific
omics variations that characterize different types of cancers and
phenotypes of a cancer (Cho, 2013).
From the clinical perspective, understanding the metabolic
pathways associated with life threatening conditions, such as
cancer, could be extremely valuable in decreasing the burden of
disease. With saliva-based DNA screening tests already available
for chair-side use in dentistry for HNC, we can envision a saliva-
based screening or diagnostic test that incorporates omics that
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replaces the surgical biopsy and provides a more individualized
and robust patient health, disease, or risk profile. Here, we
discussed the metabolomics of both the host (normal and
cancerous conditions) and co-existing microbiota (Figure 1A).
In addition, we organized the differentially expressed metabolites
from previous publications by sample types (saliva, blood and
urine, cells and tissues) and detection methods (Figures 1B,C).
The full integration and routine inclusion of metabolomics
in the clinic has yet to be implemented, however, continued
research and translational efforts will reinforce the promise
of this evolving technology and science. Studies to date have
been conducted with relatively small patient sample sizes, with
different sample types and detection methods. In the future, it
will be critical to follow up with larger, more comprehensive
population studies to confirm the validity of the current
findings. In addition, sharing detailed sample collection and
analytical methods between investigators will be essential to
conduct sound HNC metabolomics research. From the systems
biology perspective, the integration of other omics data with
metabolomics data will be required for a greater understanding
of cancer biology.
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